Product logins

Find logins to all Clarivate products below.


Gynecological Devices | Market Insights | Japan | 2022

The deferral or cancellation of nonessential procedures due to the COVID-19 pandemic negatively impacted the Japanese gynecological device market in 2020; however, the market will show strong recovery in 2021, although the pace of recovery will be slow in some segments, including capital equipment such as hysteroscopes. Following the short-term impact of the global pandemic, the market will resume modest growth through 2030, supported by technological innovations and marketing efforts by manufacturers and the continuing shift toward office-based procedures.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Gynecological devices in Japan across an 11-year period.

Related Medtech Insights Reports

Report
Diagnostic Imaging Systems – Market Insights – Japan
Japan’s diagnostic imaging system market will experience slow growth through 2034, driven by continuous technological advancement and rising hospital demand for efficient, patient-centric imaging…
Report
Laparoscopic Devices – Market Insights – Japan
The Japanese laparoscopic device market will expand modestly through 2034, driven by rising demand for MIS procedures among the country’s rapidly aging population. Additionally, the adoption of…
Report
Gynecological Devices – Market Insights – United States
The US gynecological device market will grow slowly through 2034, supported by the country’s aging female population, rising demand for hormonal IUDs and ARC devices, and gradual uptake of…
Report
Urological Devices – Market Insights – Japan
The Japanese urological device market will continue to expand through 2034, driven by the rising prevalence of risk factors for urological disorders, such as the growing burden of metabolic…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Japan
The Japanese EP mapping and ablation device market will experience moderate growth through 2034, supported by rising cardiac arrhythmia prevalence, broader treatment accessibility, and ongoing…